CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging-Reference-Cited by-同舟云学术

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging

Published:2020-06 Issue:3 Volume:295 Page:606-615
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Ulaner Gary A.¹^ORCID,Sobol Nicholas B.¹,O’Donoghue Joseph A.¹^ORCID,Kirov Assen S.¹^ORCID,Riedl Christopher C.¹^ORCID,Min Ryan¹^ORCID,Smith Eric¹,Carter Lukas M.¹^ORCID,Lyashchenko Serge K.¹,Lewis Jason S.¹^ORCID,Landgren C. Ola¹^ORCID

Affiliation:

1. From the Department of Radiology (G.A.U., N.B.S., C.C.R., R.M., L.M.C., S.K.L., J.S.L.), Department of Medical Physics (J.A.O., A.S.K.), Myeloma Service, Department of Medicine (E.S., C.O.L.), and Molecular Pharmacology Program (J.S.L.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; and Department of Radiology, Weill Cornell Medical College, New York, NY (G.A.U., C.C.R., J.S.L.).

Funder

National Institutes of Health

National Cancer Institute

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology, Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2020192621

Reference47 articles.

1. Clinical course and prognosis of non-secretory multiple myeloma

2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

2. Trends in cancer imaging;Trends in Cancer;2024-09

3. EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

4. Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging;Pharmaceutics;2024-06-30

5. Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions;Current Oncology Reports;2024-04-27